secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2025-06-04T23:59:59+00:00
Accession:  0001193125-25-134886
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Apellis shareholders elect three Class II directors and ratify Deloitte as auditor at 2025 annual meeting
--------------------------------------------------------------------------------

- Elected A. Sinclair Dunlop (54.1M for, 26.0M withheld), Alec Machiels (62.3M for, 17.8M withheld), Keli Walbert (76.95M for, 3.18M withheld) as Class II directors for three-year terms.
- Ratified Deloitte & Touche as independent auditor for FY2025 with 103.9M for, 54.6K against, 116.2K abstain.
- Approved non-binding advisory vote on named executive officer compensation: 75.9M for, 4.17M against, 59.9K abstain.
- Recommended future say-on-pay votes every year (79.86M for 1-year); company will hold annual advisory votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312525134886/0001193125-25-134886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312525134886/d85723d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-134886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer